Drug
Paclitaxel-Angiopep-2 conjugate clinical trials
Also written ANG1005.
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2007 (2)
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2011 | 1 |
| 2014 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 0
Angiochem Inc (5)
Related medicines
As reviewed, each with the page that says it.
- One of Antimitotic Agents source
Studies
Open first, then newest update. How each study uses paclitaxel-Angiopep-2 conjugate is read from its arms, and is right about nine times in ten.
Testing it · 5
- ANG1005 in Leptomeningeal Disease From Breast CancerStatus unknownPhase 3Angiochem IncNCT03613181Written as ANG1005
- ANG1005 in Breast Cancer Patients With Recurrent Brain MetastasesCompletedPhase 2Angiochem IncNCT02048059Written as ANG1005
- GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)TerminatedPhase 2Angiochem IncNCT01497665Written as GRN1005
- A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant GliomaCompletedPhase 1Angiochem IncNCT00539344Written as ANG1005
- A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain CancerCompletedPhase 1Angiochem IncNCT00539383Written as ANG1005
Given in every arm · 3 — paclitaxel-Angiopep-2 conjugate is usual care beside what is tested
- ANG1005 in Patients With Recurrent High-Grade GliomaCompletedPhase 2Angiochem IncNCT01967810Written as ANG1005
- GRN1005 for Brain Metastases From Breast or Lung CancerWithdrawnPhase 2National Cancer Institute (NCI)NCT01679743Written as GRN 1005
- GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain MetastasesCompletedPhase 2Angiochem IncNCT01480583Written as GRN1005